Literature DB >> 19519406

The TRAIL to viral pathogenesis: the good, the bad and the ugly.

Nathan Cummins1, Andrew Badley.   

Abstract

Since the discovery of Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) in 1995, much has been learned about the protein, its receptors and signaling cascade to induce apoptosis and the regulation of its expression. However, the physiologic role or roles that TRAIL may play in vivo are still being explored. The expression of TRAIL on effector T cells and the ability of TRAIL to induce apoptosis in virally infected cells provided early clues that TRAIL may play an active role in the immune defense against viral infections. However, increasing evidence is emerging that TRAIL may have a dual function in the immune system, both as a means to kill virally infected cells and in the regulation of cytokine production. TRAIL has been implicated in the immune response to viral infections (good), and in the pathogenesis of multiple viral infections (bad). Furthermore, several viruses have evolved mechanisms to manipulate TRAIL signaling to increase viral replication (ugly). It is likely that whether TRAIL ultimately has a proviral or antiviral effect will be dependent on the specific virus and the overall cytokine milieu of the host. Knowledge of the factors that determine whether TRAIL is proviral or antiviral is important because the TRAIL system may become a target for development of novel antiviral therapies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19519406      PMCID: PMC3149795          DOI: 10.2174/156652409788167078

Source DB:  PubMed          Journal:  Curr Mol Med        ISSN: 1566-5240            Impact factor:   2.222


  115 in total

1.  Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.

Authors:  Senji Tafuku; Takehiro Matsuda; Hirochika Kawakami; Mariko Tomita; Hideo Yagita; Naoki Mori
Journal:  Eur J Haematol       Date:  2006-01       Impact factor: 2.997

2.  Association between TRAIL expression on peripheral blood lymphocytes and liver damage in chronic hepatitis B.

Authors:  Gong-Ying Chen; Jian-Qin He; Guo-Cai Lu; Ming-Wei Li; Chen-Huai Xu; Wei-Wei Fan; Chen Zhou; Zhi Chen
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

3.  Acquired T-cell sensitivity to TRAIL mediated killing during HIV infection is regulated by CXCR4-gp120 interactions.

Authors:  Julian J Lum; David J Schnepple; Andrew D Badley
Journal:  AIDS       Date:  2005-07-22       Impact factor: 4.177

4.  CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis.

Authors:  Jean-Philippe Herbeuval; Jean-Charles Grivel; Adriano Boasso; Andrew W Hardy; Claire Chougnet; Matthew J Dolan; Hideo Yagita; Jeffrey D Lifson; Gene M Shearer
Journal:  Blood       Date:  2005-07-26       Impact factor: 22.113

5.  Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells.

Authors:  Jean-Philippe Herbeuval; Andrew W Hardy; Adriano Boasso; Stephanie A Anderson; Matthew J Dolan; Michel Dy; Gene M Shearer
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-20       Impact factor: 11.205

6.  E2 of hepatitis C virus inhibits apoptosis.

Authors:  Song Hee Lee; Yoon Ki Kim; Chon Saeng Kim; Su Kyoung Seol; Joonhyun Kim; Sungchan Cho; Young Lan Song; Ralf Bartenschlager; Sung Key Jang
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

7.  [Soluble tumor necrosis factor related apoptosis inducing ligand (sTRAIL) and clinical outcome of HBV infection in human].

Authors:  Feng-e Yue; Dian-yong Liu; Jing Song; Li-ning Zhang
Journal:  Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi       Date:  2005-06

8.  Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake.

Authors:  B Mundt; T Wirth; L Zender; M Waltemathe; C Trautwein; M P Manns; F Kühnel; S Kubicka
Journal:  Gut       Date:  2005-11       Impact factor: 23.059

9.  Involvement of tumor necrosis factor-related apoptosis-inducing ligand and tumor necrosis factor-related apoptosis-inducing ligand receptors in viral hepatic diseases.

Authors:  Yukiko Saitou; Katsuya Shiraki; Hiroyuki Fuke; Tomoko Inoue; Kazumi Miyashita; Yutaka Yamanaka; Yumi Yamaguchi; Norihik Yamamoto; Keiichi Ito; Kazushi Sugimoto; Takeshi Nakano
Journal:  Hum Pathol       Date:  2005-10       Impact factor: 3.466

10.  Role of tumor necrosis factor-related apoptosis-inducing ligand in immune response to influenza virus infection in mice.

Authors:  Eri Ishikawa; Masatoshi Nakazawa; Masahiro Yoshinari; Mutsuhiko Minami
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

View more
  27 in total

Review 1.  Resistance to TRAIL and how to surmount it.

Authors:  Danijela Maksimovic-Ivanic; Stanislava Stosic-Grujicic; Ferdinando Nicoletti; Sanja Mijatovic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

2.  TRAILshort Protects against CD4 T Cell Death during Acute HIV Infection.

Authors:  Sekar Natesampillai; Ana C Paim; Nathan W Cummins; Aswath P Chandrasekar; Gary D Bren; Sharon R Lewin; Hans-Peter Kiem; Andrew D Badley
Journal:  J Immunol       Date:  2019-06-12       Impact factor: 5.422

3.  HIV elite control is associated with reduced TRAILshort expression.

Authors:  Ana C Paim; Nathan W Cummins; Sekar Natesampillai; Enrique Garcia-Rivera; Nicole Kogan; Ujjwal Neogi; Anders Sönnerborg; Maike Sperk; Gary D Bren; Steve Deeks; Eric Polley; Andrew D Badley
Journal:  AIDS       Date:  2019-09-01       Impact factor: 4.177

Review 4.  Tumor necrosis factor receptor/tumor necrosis factor family members in antiviral CD8 T-cell immunity.

Authors:  Shahram Salek-Ardakani; Michael Croft
Journal:  J Interferon Cytokine Res       Date:  2010-04       Impact factor: 2.607

5.  HTLV-1-infected asymptomatic carriers compared to HAM/TSP patients over-express the apoptosis- and cytotoxicity-related molecules.

Authors:  Asadollah Mohammadi; Bahare Fazeli; Zohreh Poursina; Farahnaz Tehranian; Veda Vakili; Reza Boostani; Houshang Rafatpanah
Journal:  Med Microbiol Immunol       Date:  2019-07-18       Impact factor: 3.402

6.  Polymorphism in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 is associated with poor viral response to interferon-based hepatitis C virus therapy in HIV/hepatitis C virus-coinfected individuals.

Authors:  Stacey A Rizza; Nathan W Cummins; David N Rider; Sahar Saeed; Marina B Klein; Andrew D Badley
Journal:  AIDS       Date:  2010-11-13       Impact factor: 4.177

7.  Identification of pathogenic TRAIL-expressing innate immune cells during HIV-1 infection in humanized mice by scRNA-Seq.

Authors:  Liang Cheng; Haisheng Yu; John A Wrobel; Guangming Li; Peng Liu; Zhiyuan Hu; Xiao-Ning Xu; Lishan Su
Journal:  JCI Insight       Date:  2020-06-04

8.  Human cytomegalovirus glycoprotein UL141 targets the TRAIL death receptors to thwart host innate antiviral defenses.

Authors:  Wendell Smith; Peter Tomasec; Rebecca Aicheler; Andrea Loewendorf; Ivana Nemčovičová; Eddie C Y Wang; Richard J Stanton; Matt Macauley; Paula Norris; Laure Willen; Eva Ruckova; Akio Nomoto; Pascal Schneider; Gabriele Hahn; Dirk M Zajonc; Carl F Ware; Gavin W G Wilkinson; Chris A Benedict
Journal:  Cell Host Microbe       Date:  2013-03-13       Impact factor: 21.023

9.  Dengue virus activates membrane TRAIL relocalization and IFN-α production by human plasmacytoid dendritic cells in vitro and in vivo.

Authors:  Mariana Gandini; Christophe Gras; Elzinandes Leal Azeredo; Luzia Maria de Oliveira Pinto; Nikaïa Smith; Philippe Despres; Rivaldo Venâncio da Cunha; Luiz José de Souza; Claire Fernandes Kubelka; Jean-Philippe Herbeuval
Journal:  PLoS Negl Trop Dis       Date:  2013-06-06

10.  Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion.

Authors:  Dimitra Peppa; Upkar S Gill; Gary Reynolds; Nicholas J W Easom; Laura J Pallett; Anna Schurich; Lorenzo Micco; Gaia Nebbia; Harsimran D Singh; David H Adams; Patrick T F Kennedy; Mala K Maini
Journal:  J Exp Med       Date:  2012-12-17       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.